{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-110462","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.798266+00:00","generated_at":"2026-05-30T23:21:11.924821+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Trevi Therapeutics names James Cassella Chief Development Officer; CMO David Clark departs","bullets":["James Cassella appointed CDO effective Sept 30, 2024; he resigned from the Board on that date.","David Clark stepped down as CMO effective Sept 27, 2024, to care for a family member; will consult at $400/hour.","Cassella has 35+ years CNS drug development experience, including CDO at Concert Pharmaceuticals and FDA approval of Leqselvi.","Company is advancing Haduvio for IPF cough and refractory chronic cough; pivotal program and regulatory submission planned."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-110462","json":"https://secwatch.observer/filing/0000950170-24-110462.json","markdown":"https://secwatch.observer/filing/0000950170-24-110462.md","text":"https://secwatch.observer/filing/0000950170-24-110462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/trvi-20240927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T23:21:11.924821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"147dc65039","claim":"David Clark departed as Chief Medical Officer at Trevi Therapeutics, Inc..","evidence_excerpt":"David Clark, MBChB, MRCP, had stepped down as the Company’s Chief Medical Officer, effective as of September 27, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"80f7daf8b6","claim":"James Cassella resigned as Member of the Board of Directors at Trevi Therapeutics, Inc..","evidence_excerpt":"Dr. Cassella resigned from his position as a member of the Board of Directors of the Company, effective as of September 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"c2931de05a","claim":"James Cassella was appointed as Chief Development Officer at Trevi Therapeutics, Inc..","evidence_excerpt":"announced that James Cassella, Ph.D., had agreed to join the Company as its Chief Development Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024110462/0000950170-24-110462-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}